0000950170-24-071539.txt : 20240610
0000950170-24-071539.hdr.sgml : 20240610
20240610194301
ACCESSION NUMBER: 0000950170-24-071539
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240606
FILED AS OF DATE: 20240610
DATE AS OF CHANGE: 20240610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bredt David
CENTRAL INDEX KEY: 0002022087
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-42121
FILM NUMBER: 241034340
MAIL ADDRESS:
STREET 1: C/O RAPPORT THERAPEUTICS
STREET 2: 1325 BOYLSTON ST., SUITE 401
CITY: BOSTON
STATE: MA
ZIP: 02215
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Rapport Therapeutics, Inc.
CENTRAL INDEX KEY: 0002012593
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 880724208
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1325 BOYLSTON STREET
STREET 2: SUITE 401
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: 857-321-8020
MAIL ADDRESS:
STREET 1: 1325 BOYLSTON STREET
STREET 2: SUITE 401
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
ownership.xml
4
X0508
4
2024-06-06
0002012593
Rapport Therapeutics, Inc.
RAPP
0002022087
Bredt David
RAPPORT THERAPEUTICS, INC.
1325 BOYLSTON STREET, SUITE 401
BOSTON
MA
02215
false
true
false
false
Chief Scientific Officer
false
Stock Option (Right to Buy)
17
2024-06-06
4
A
false
28302
0.00
A
2034-06-05
Common Stock
28302
28302
D
25% of the shares underlying this option shall vest and become exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
/s/ Cheryl Gault, Attorney-in-Fact
2024-06-10